Commercial Kardigan targets IPO to support cardiology pipeline progression Pharmaceutical TechnologyKardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical pipeline.CardiovascularRead full story pharminent May 27, 2026 (Last updated: May 27, 2026) Pharmaceutical Technology Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical pipeline. Cardiovascular Read full story Post navigation Previous: FDA delays verdict on AZ breast cancer drugNext: Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026
